Aquestive Therapeutics Inc 近日宣布，已获得美国食品药品监督管理局（FDA）针对其药代动力学（PK）研究及人因工程学（HF）研究方案所提出的澄清反馈意见。这一进展标志着公司在相关药物研发项目上取得了重要的监管沟通成果。
Aquestive Therapeutics Inc 近日宣布，已获得美国食品药品监督管理局（FDA）针对其药代动力学（PK）研究及人因工程学（HF）研究方案所提出的澄清反馈意见。这一进展标志着公司在相关药物研发项目上取得了重要的监管沟通成果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.